Rhythm Pharmaceuticals, a clinical-stage biotech developing peptide-based therapeutics to treat obesity, filed on Tuesday with the SEC to raise up to $115 million in an initial public offering.
The Boston, MA-based company was founded in 2008 and plans to list on the Nasdaq under the symbol RYTM. Rhythm Pharmaceuticals filed confidentially on October 13, 2015. Morgan Stanley, Merrill Lynch and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
